AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Absci shares surge 10.49% intraday as AI-designed antibody ABS-201 enters clinical evaluation for androgenetic alopecia.
ByAinvest
Thursday, Dec 4, 2025 10:51 am ET1min read
Absci surged 10.49% intraday trading, as the company announced its AI-designed antibody ABS-201 has begun clinical evaluation in a Phase 1/2a trial for androgenetic alopecia. On December 4, 2025, the first healthy volunteers received the drug, marking the start of the clinical assessment phase. Absci is a clinical-stage biopharmaceutical company leveraging generative AI to develop breakthrough antibody therapies targeting challenging targets such as the PRLR receptor.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet